NewGen Announces Reverse Stock Split
NewGen (NASDAQ: NIVF) announced a 1-for-20 reverse stock split of all issued and unissued shares, approved by the Board on January 21, 2025. The company's Class A Ordinary Shares will begin trading on a split-adjusted basis on February 11, 2025, under the same ticker NIVF but with a new CUSIP number G0544E204.
The reverse split will reduce outstanding Class A Ordinary Shares from approximately 27.07 million to 1.35 million. All options, warrants, and convertible securities will be adjusted accordingly. The company will issue one full post-split share for any fractional shares resulting from the process.
The primary purpose of this reverse split is to regain compliance with Nasdaq's $1.00 per share minimum bid price requirement, for which the company has until April 7, 2025, to comply. Continental Stock Transfer & Trust Company will serve as the transfer agent for this process.
NewGen (NASDAQ: NIVF) ha annunciato un frazionamento azionario inverso 1-per-20 di tutte le azioni emesse e non emesse, approvato dal Consiglio il 21 gennaio 2025. Le azioni ordinarie di Classe A dell'azienda inizieranno a essere negoziate in base all'aggiustamento del frazionamento l'11 febbraio 2025, con lo stesso simbolo NIVF ma con un nuovo numero CUSIP G0544E204.
Il frazionamento inverso ridurrà le azioni ordinarie di Classe A in circolazione da circa 27,07 milioni a 1,35 milioni. Tutte le opzioni, i warrant e i titoli convertibili saranno adeguati di conseguenza. L'azienda emetterà un'azione intera post-frazionamento per eventuali azioni frazionate risultanti dal processo.
Lo scopo principale di questo frazionamento inverso è quello di ripristinare la conformità con il requisito minimo di prezzo di offerta di $1,00 per azione di Nasdaq, per il quale l'azienda ha tempo fino al 7 aprile 2025 per adeguarsi. La Continental Stock Transfer & Trust Company fungerà da agente di trasferimento per questo processo.
NewGen (NASDAQ: NIVF) anunció un desdoblamiento inverso de acciones de 1 por 20 de todas las acciones emitidas y no emitidas, aprobado por la Junta el 21 de enero de 2025. Las acciones ordinarias de Clase A de la compañía comenzarán a cotizar en una base ajustada por el desdoblamiento el 11 de febrero de 2025, bajo el mismo símbolo NIVF pero con un nuevo número CUSIP G0544E204.
El desdoblamiento inverso reducirá las acciones ordinarias de Clase A en circulación de aproximadamente 27,07 millones a 1,35 millones. Todas las opciones, garantías y valores convertibles se ajustarán en consecuencia. La compañía emitirá una acción completa post-desdoblamiento por cualquier acción fraccionaria resultante del proceso.
El propósito principal de este desdoblamiento inverso es recuperar la conformidad con el requisito mínimo de precio de oferta de $1.00 por acción de Nasdaq, para lo cual la compañía tiene hasta el 7 de abril de 2025 para cumplir. La Continental Stock Transfer & Trust Company actuará como agente de transferencia para este proceso.
뉴젠 (NASDAQ: NIVF)은 2025년 1월 21일 이사회에서 승인된 발행 및 미발행 주식에 대한 1주당 20주 비율의 주식 병합을 발표했습니다. 회사의 클래스 A 보통주는 2025년 2월 11일부터는 동일한 심볼 NIVF로 조정된 비율로 거래를 시작하되, 새로운 CUSIP 번호 G0544E204로 거래됩니다.
이번 비율 조정으로 클래스 A 보통주의 유통 주식 수는 약 2,707만 주에서 135만 주로 줄어듭니다. 모든 옵션, 보증증서 및 전환 가능한 증권은 이에 맞춰 조정됩니다. 회사는 과정에서 발생할 수 있는 모든 분할 주식에 대해 1주를 발행할 것입니다.
이번 비율 조정의 주요 목적은 나스닥의 주당 최소 제안 가격 요구 사항인 $1.00 준수를 회복하는 것입니다. 회사는 2025년 4월 7일까지 이를 준수해야 합니다. Continental Stock Transfer & Trust Company는 이 과정의 이전 에이전트 역할을 할 것입니다.
NewGen (NASDAQ: NIVF) a annoncé un regroupement inversé d'actions de 1 pour 20 pour toutes les actions émises et non émises, approuvé par le Conseil d'administration le 21 janvier 2025. Les actions ordinaires de Classe A de la société commenceront à être négociées sur une base ajustée le 11 février 2025, sous le même ticker NIVF mais avec un nouveau numéro CUSIP G0544E204.
Ce regroupement inversé réduira les actions ordinaires de Classe A en circulation d’environ 27,07 millions à 1,35 million. Toutes les options, bons de souscription et titres convertibles seront ajustés en conséquence. La société émettra une action entière après regroupement pour toute action fractionnelle résultant du processus.
Le principal objectif de ce regroupement inversé est de retrouver la conformité avec l'exigence de prix minimum d'offre de 1,00 $ par action de Nasdaq, pour laquelle la société a jusqu'au 7 avril 2025 pour se conformer. La Continental Stock Transfer & Trust Company agira en tant qu'agent de transfert pour ce processus.
NewGen (NASDAQ: NIVF) hat einen 1-für-20 Rücksplit von allen ausgegebenen und nicht ausgegebenen Aktien angekündigt, der am 21. Januar 2025 vom Vorstand genehmigt wurde. Die Aktien der Klasse A werden ab dem 11. Februar 2025 auf einer an die Anpassung des Splits angepassten Basis unter dem gleichen Ticker NIVF aber mit einer neuen CUSIP-Nummer G0544E204 gehandelt.
Der Rücksplit wird die ausgegebenen Aktien der Klasse A von etwa 27,07 Millionen auf 1,35 Millionen reduzieren. Alle Optionen, Warrants und wandelbaren Wertpapiere werden entsprechend angepasst. Das Unternehmen wird für alle durch den Prozess resultierenden Bruchanteile eine volle Nach-Split Aktie ausgeben.
Der Hauptzweck dieses Rücksplits besteht darin, die Einhaltung der Mindestgebotsanforderung von Nasdaq von 1,00 USD pro Aktie wiederzuerlangen, für die das Unternehmen bis zum 7. April 2025 Zeit hat. Die Continental Stock Transfer & Trust Company wird als Transferagentur für diesen Prozess fungieren.
- Company taking active steps to maintain Nasdaq listing compliance
- Reverse stock split indicates share price weakness
- Risk of potential delisting if minimum bid requirement isn't met by April 7, 2025
- No guarantee of compliance achievement stated in PR
Insights
NewGen's announcement of a 1-for-20 reverse stock split represents a critical turning point for the company's market presence. This corporate action, while technically maintaining proportional ownership, carries significant implications for investors and market dynamics.
The reduction from 27.07 million to 1.35 million outstanding shares is primarily aimed at regaining Nasdaq compliance before the April 7, 2025 deadline. However, historical market data suggests reverse splits often face challenging headwinds. While they can temporarily boost share price, they frequently signal underlying financial stress to investors.
Key considerations for stakeholders include:
- Reduced trading liquidity due to fewer outstanding shares, potentially leading to increased volatility
- Higher broker fees for smaller retail investors due to larger per-share trading costs
- Market perception challenges, as reverse splits are often associated with struggling companies
The proportional adjustment of options, warrants and convertible securities maintains theoretical value equality but may impact trading dynamics. While the company provides accommodation for fractional shares by rounding up, this technical aspect is overshadowed by broader market implications.
Historical precedent suggests that companies implementing reverse splits face significant hurdles in maintaining post-split price levels. Success typically depends on demonstrating fundamental business improvements concurrent with the split. For NewGen, maintaining Nasdaq listing status is important for institutional investment access and market visibility, making this a pivotal moment for the company's future market position.
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025
BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it is implementing a reverse stock split of all of the Company's issued and unissued shares, including the Class A ordinary shares with no par value (the "Class A Ordinary Shares"), Class B ordinary shares with no par value and preferred shares with no par value, at an exchange ratio of one (1) share for twenty (20) shares (the “Reverse Stock Split”). The Reverse Stock Split was approved by the Company’s Board of Directors on January 21, 2025.
The Company’s Class A Ordinary Shares will begin trading on the Nasdaq Global Market on a post-Reverse Stock Split basis under the current ticker symbol “NIVF” at the commencement of trading on February 11, 2025, and will trade under the new CUSIP number G0544E204.
The Reverse Stock Split will reduce the number of outstanding Class A Ordinary Shares of the Company from approximately 27.07 million to approximately 1.35 million. Every twenty (20) outstanding Class A Ordinary Shares will be combined into and automatically become one post-Reverse Stock Split Class A Ordinary Share. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary Share to any shareholder who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other convertible securities are exercisable or convertible by twenty (20) in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.
The Company is primarily implementing the reverse stock split to enable it to regain compliance with the Nasdaq
The Company’s transfer agent, Continental Stock Transfer & Trust Company (“Continental”), will serve as the transfer agent for the Reverse Stock Split.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen’s management team collectively has over a decade of experience in the fertility industry. NewGen’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, the Company’s inability to meet or exceed its financial projections, or changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

FAQ
What is the exchange ratio for NIVF's reverse stock split in 2025?
When will NIVF's reverse split shares begin trading on Nasdaq?
How many shares will NIVF have outstanding after the reverse split?
What is the deadline for NIVF to meet Nasdaq's minimum bid requirement?